43 Result(s)

Article

Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide

Therapy-related acute promyelocytic leukemia (t-APL) is relatively rare, with limited data on outcome after treatment with arsenic trioxide (ATO) compared to standard intensive chemotherapy (CTX). We evaluated...

S Kayser, J Krzykalla, M A Elliott, K Norsworthy, P Gonzales, R K Hills… in Leukemia (2017)

Article

Evolution of NPM1-negative therapy-related myelodysplastic syndromes following curative treatment of NPM1-mutant AML

S Herold, K Sockel, C Sayehli, R Herbst, U Dührsen, U Oelschlägel, A Böttner… in Leukemia (2017)

Article

Donor cell leukemia: evidence for multiple preleukemic clones and parallel long term clonal evolution in donor and recipient

S Herold, M Kuhn, M v Bonin, T Stange, U Platzbecker, J Radke, T Lange… in Leukemia (2017)

Article

Myelodysplastic syndromes and bone loss in mice and men

H Weidner, M Rauner, F Trautmann, J Schmitt, E Balaian, A Mies, S Helas… in Leukemia (2017)

Article

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis

Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is repor...

R F Schlenk, F Stegelmann, A Reiter, E Jost, N Gattermann, H Hebart, C Waller… in Leukemia (2017)

Article

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)

M Mossner, J-C Jann, D Nowak, U Platzbecker, A Giagounidis, K Götze, A Letsch… in Leukemia (2016)

Article

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5)

E Schuler, A Giagounidis, D Haase, K Shirneshan, G Büsche, U Platzbecker… in Leukemia (2016)

Article

Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial

In patients with relapsed or refractory (r/r) acute myeloid leukemia (AML), long-term disease control can only be achieved by allogeneic hematopoietic stem cell transplantation (HSCT). We studied the safety an...

J M Middeke, R Herbst, S Parmentier, G Bug, M Hänel, G Stuhler… in Leukemia (2016)

Article

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q

M Heuser, M Meggendorfer, M M A Cruz, J Fabisch, S Klesse, L Köhler, G Göhring… in Leukemia (2015)

Article

Which prognostic score in MDS? Both!

U Platzbecker in Leukemia (2015)

Article

Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial

The optimal timing of allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) is controversial. We report on 1179 patients with a median age of 48 years who were randomized upf...

J Schetelig, M Schaich, K Schäfer-Eckart, M Hänel, W E Aulitzky, H Einsele… in Leukemia (2015)